Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2482人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866395, encodeId=716818663956e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：基于肿瘤大小的Siewert II/III型食管胃交界处腺癌(AEG)患者幽门淋巴结清扫(PLNs)的生存影响, objectType=article, longId=221515, objectId=0df92215158c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df92215158c, replyNumber=0, likeNumber=52, createdTime=2022-01-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df92215158c, moduleTitle=Front Oncol：基于肿瘤大小的Siewert II/III型食管胃交界处腺癌(AEG)患者幽门淋巴结清扫(PLNs)的生存影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0df92215158c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866136, encodeId=5bd11866136e7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Int J Radiat Oncol Biol Phys：颅咽管瘤手术术后辅以质子治疗有益于患者预后, objectType=article, longId=213353, objectId=279a21335342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=279a21335342, replyNumber=0, likeNumber=78, createdTime=2021-06-27, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=279a21335342, moduleTitle=Int J Radiat Oncol Biol Phys：颅咽管瘤手术术后辅以质子治疗有益于患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=279a21335342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866216, encodeId=bff718662166c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Oncol：首次报道！LOC105371267变异对中国北方汉族女性乳腺癌易感性的影响, objectType=article, longId=216906, objectId=cdc221690687, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdc221690687, replyNumber=0, likeNumber=69, createdTime=2022-08-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdc221690687, moduleTitle=J Oncol：首次报道！LOC105371267变异对中国北方汉族女性乳腺癌易感性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdc221690687)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866130, encodeId=32451866130ac, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：非转移去势抵抗性前列腺癌的分子亚型与Apalutamide治疗结果差异的关系 , objectType=article, longId=213257, objectId=9d5921325e93, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d5921325e93, replyNumber=0, likeNumber=73, createdTime=2021-07-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d5921325e93, moduleTitle=JAMA Oncol：非转移去势抵抗性前列腺癌的分子亚型与Apalutamide治疗结果差异的关系 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d5921325e93)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866188, encodeId=71f718661880c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：meta分析显示化疗联合曲妥珠单抗对HER2阳性乳腺癌患者，能够显著降低复发和死亡风险, objectType=article, longId=215483, objectId=b69b21548371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b69b21548371, replyNumber=0, likeNumber=80, createdTime=2022-02-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b69b21548371, moduleTitle=Lancet Oncol：meta分析显示化疗联合曲妥珠单抗对HER2阳性乳腺癌患者，能够显著降低复发和死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b69b21548371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866158, encodeId=1f5c186615814, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol: 肿瘤患者营养支持可降低死亡率：一项前瞻性随机研究的二次分析结果, objectType=article, longId=214427, objectId=dff221442e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dff221442e84, replyNumber=0, likeNumber=76, createdTime=2022-01-17, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dff221442e84, moduleTitle=Ann Oncol: 肿瘤患者营养支持可降低死亡率：一项前瞻性随机研究的二次分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dff221442e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866357, encodeId=e7bf186635eec, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良, objectType=article, longId=220543, objectId=20ce220543ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20ce220543ab, replyNumber=0, likeNumber=72, createdTime=2021-12-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20ce220543ab, moduleTitle=J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20ce220543ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866239, encodeId=c63e1866239f7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Gynecol Oncol：宫颈病变LEEP和激光锥切术复发率：5年随访研究结果, objectType=article, longId=217448, objectId=f68d21e448b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f68d21e448b7, replyNumber=0, likeNumber=61, createdTime=2022-03-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f68d21e448b7, moduleTitle=Gynecol Oncol：宫颈病变LEEP和激光锥切术复发率：5年随访研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f68d21e448b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866362, encodeId=b84d186636271, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol:非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较, objectType=article, longId=220759, objectId=9414220e5918, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9414220e5918, replyNumber=0, likeNumber=46, createdTime=2022-06-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9414220e5918, moduleTitle=Front Oncol:非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9414220e5918)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866212, encodeId=d3e41866212c5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：3期| 纳武单抗 vs 吉西他滨或阿霉素用于铂耐药的卵巢癌的疗效和安全性, objectType=article, longId=216715, objectId=565a216e15f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=565a216e15f8, replyNumber=0, likeNumber=124, createdTime=2022-03-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=565a216e15f8, moduleTitle=J Clin Oncol：3期| 纳武单抗 vs 吉西他滨或阿霉素用于铂耐药的卵巢癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=565a216e15f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866501, encodeId=14b41866501b5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, objectType=article, longId=295378, objectId=2fbf2953e8d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fbf2953e8d9, replyNumber=0, likeNumber=100, createdTime=2022-07-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fbf2953e8d9, moduleTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fbf2953e8d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866440, encodeId=559f186644092, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, objectType=article, longId=293055, objectId=28ee293055ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ee293055ec, replyNumber=0, likeNumber=73, createdTime=2022-12-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ee293055ec, moduleTitle=Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ee293055ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866393, encodeId=c972186639373, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：内分泌联合或不联合abemaciclib（阿贝西利）辅助治疗HR+/HER2-早期高危乳腺癌患者的疗效, objectType=article, longId=221443, objectId=d7bd22144352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7bd22144352, replyNumber=0, likeNumber=60, createdTime=2022-05-27, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7bd22144352, moduleTitle=Ann Oncol：内分泌联合或不联合abemaciclib（阿贝西利）辅助治疗HR+/HER2-早期高危乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7bd22144352)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866157, encodeId=6634186615e1c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, objectType=article, longId=214414, objectId=2f7c2144147c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f7c2144147c, replyNumber=0, likeNumber=119, createdTime=2022-06-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f7c2144147c, moduleTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f7c2144147c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866353, encodeId=7494186635329, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, objectType=article, longId=220495, objectId=dbd22204957c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbd22204957c, replyNumber=0, likeNumber=0, createdTime=2022-03-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbd22204957c, moduleTitle=Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbd22204957c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866598, encodeId=ffda186659857, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Hematol Oncol：同种异体造血干细胞移植治疗成人原发性噬血细胞性淋巴组织细胞增多症是安全有效的, objectType=article, longId=726602, objectId=dd6ae26602a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd6ae26602a6, replyNumber=0, likeNumber=65, createdTime=2022-09-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd6ae26602a6, moduleTitle=Hematol Oncol：同种异体造血干细胞移植治疗成人原发性噬血细胞性淋巴组织细胞增多症是安全有效的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd6ae26602a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866491, encodeId=719f1866491a1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素, objectType=article, longId=295136, objectId=26002951366f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26002951366f, replyNumber=0, likeNumber=74, createdTime=2022-12-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26002951366f, moduleTitle=Front Oncol：宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26002951366f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866250, encodeId=3bee186625010, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：EBV感染相关胃癌(EBVaGC)的临床病理特征和化疗应答, objectType=article, longId=217677, objectId=9a8921e677bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a8921e677bb, replyNumber=0, likeNumber=56, createdTime=2021-12-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a8921e677bb, moduleTitle=Front Oncol：EBV感染相关胃癌(EBVaGC)的临床病理特征和化疗应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a8921e677bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866297, encodeId=3795186629e05, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：化疗对I期鼻咽癌患者的预后影响, objectType=article, longId=218718, objectId=b245218e1861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b245218e1861, replyNumber=0, likeNumber=86, createdTime=2022-06-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b245218e1861, moduleTitle=Front Oncol：化疗对I期鼻咽癌患者的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b245218e1861)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866527, encodeId=b8df186652efc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：进展性胶质母细胞瘤(GBM)进行完全切除和不完全切除可延长进展后生存, objectType=article, longId=299346, objectId=1f332993462c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f332993462c, replyNumber=0, likeNumber=74, createdTime=2022-11-17, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f332993462c, moduleTitle=Front Oncol：进展性胶质母细胞瘤(GBM)进行完全切除和不完全切除可延长进展后生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f332993462c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：基于肿瘤大小的Siewert II/III型食管胃交界处腺癌(AEG)患者幽门淋巴结清扫(PLNs)的生存影响

2022-01-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Int J Radiat Oncol Biol Phys：颅咽管瘤手术术后辅以质子治疗有益于患者预后

2021-06-27

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Oncol：首次报道！LOC105371267变异对中国北方汉族女性乳腺癌易感性的影响

2022-08-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：非转移去势抵抗性前列腺癌的分子亚型与Apalutamide治疗结果差异的关系

2021-07-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：meta分析显示化疗联合曲妥珠单抗对HER2阳性乳腺癌患者，能够显著降低复发和死亡风险

2022-02-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol: 肿瘤患者营养支持可降低死亡率：一项前瞻性随机研究的二次分析结果

2022-01-17

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：博纳吐单抗无反应和高疾病负荷提示，B-ALL患者采用CD19-CAR治疗的预后不良

2021-12-05

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Gynecol Oncol：宫颈病变LEEP和激光锥切术复发率：5年随访研究结果

2022-03-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol:非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较

2022-06-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：3期| 纳武单抗 vs 吉西他滨或阿霉素用于铂耐药的卵巢癌的疗效和安全性

2022-03-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后

2022-07-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：中肿石明教授团队回顾性研究发现仑伐替尼+特瑞普利单抗+肝动脉灌注化疗（HAIC）可改善晚期肝细胞癌患者预后

2022-12-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：内分泌联合或不联合abemaciclib（阿贝西利）辅助治疗HR+/HER2-早期高危乳腺癌患者的疗效

2022-05-27

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性

2022-06-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：Lenvatinib(仑伐替尼，LEN)联合免疫检查点抑制剂(ICIs)治疗晚期肝细胞癌（HCC）患者的安全性和有效性

2022-03-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Hematol Oncol：同种异体造血干细胞移植治疗成人原发性噬血细胞性淋巴组织细胞增多症是安全有效的

2022-09-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素

2022-12-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：EBV感染相关胃癌(EBVaGC)的临床病理特征和化疗应答

2021-12-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：化疗对I期鼻咽癌患者的预后影响

2022-06-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：进展性胶质母细胞瘤(GBM)进行完全切除和不完全切除可延长进展后生存

2022-11-17

科室
- - 订阅+
  - 更多科室
工具
服务